Barclays PLC Has $1.31 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Barclays PLC boosted its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 171.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,241 shares of the company’s stock after buying an additional 100,498 shares during the period. Barclays PLC owned approximately 0.10% of Wave Life Sciences worth $1,307,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after buying an additional 856 shares during the period. Mackenzie Financial Corp raised its position in Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after buying an additional 1,905 shares during the period. Rhumbline Advisers raised its position in Wave Life Sciences by 3.4% during the second quarter. Rhumbline Advisers now owns 125,834 shares of the company’s stock valued at $628,000 after buying an additional 4,092 shares during the period. The Manufacturers Life Insurance Company raised its position in Wave Life Sciences by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company’s stock valued at $698,000 after buying an additional 4,914 shares during the period. Finally, US Bancorp DE raised its position in Wave Life Sciences by 53.9% during the third quarter. US Bancorp DE now owns 18,043 shares of the company’s stock valued at $148,000 after buying an additional 6,316 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Stock Performance

WVE opened at $11.54 on Monday. The company has a market cap of $1.76 billion, a PE ratio of -10.40 and a beta of -1.07. The stock has a 50-day moving average of $14.03 and a 200-day moving average of $9.78. Wave Life Sciences Ltd. has a 52-week low of $3.50 and a 52-week high of $16.74.

Analyst Ratings Changes

Several brokerages have weighed in on WVE. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. Leerink Partners upped their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Wells Fargo & Company upped their target price on Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. B. Riley upped their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, Truist Financial upped their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Wave Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $22.22.

Insider Transactions at Wave Life Sciences

In related news, insider Chris Francis sold 36,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $576,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paul Bolno sold 90,474 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $15.00, for a total value of $1,357,110.00. Following the sale, the chief executive officer now owns 268,585 shares of the company’s stock, valued at approximately $4,028,775. The trade was a 25.20 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 436,544 shares of company stock worth $6,271,569. 29.10% of the stock is owned by corporate insiders.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.